Acute Tumor Lysis Syndrome after Transcatheter Arterial Chemoembolization in a Patient with Hepatocellular Carcinoma

Dilip Sharma,Zhenggang Ren,Jinglin Xia,Shenglong Ye
DOI: https://doi.org/10.1016/j.ejrex.2006.02.005
2006-01-01
European Journal of Radiology Extra
Abstract:Acute tumor lysis syndrome is a very serious and sometimes life-threatening complication of cancer therapy [Oztop I, Demirkan B, Yaren A, et al. Rapid tumor lysis syndrome in a patient with metastatic colon cancer as a complication of treatment with 5-fluorouracil/leucoverin and irinotecan. Tumori 2004;90(5):514–6]. It can be defined as a pattern of metabolic abnormalities resulting from treatment-related tumor necrosis or fulminant apoptosis. The pathogenesis of tumor lysis syndrome is related to rapid tumor cell destruction, which may result in the release of intracellular ions and metabolic byproducts into the systemic circulation. Acute renal failure may frequently complicate tumor lysis syndrome and is mainly due to renal tubule precipitation of uric acid, calcium phosphate, or hypoxanthine [Locatelli F, Rossi, F. Incidence and pathogenesis of tumor lysis syndrome. Contrib Nephrol 2005;147:61–8]. The metabolic abnormalities observed in patients with tumor lysis syndrome include hyperkalemia, hyperuricemia, and hyperphosphatemia with secondary hypocalcemia. There are few reports of acute tumor lysis syndrome following transcatheter arterial chemoembolisation (TACE) in patients with HCC. Recently a case of acute tumor lysis syndrome after transcatheter arterial chemoembolisation (TACE) was managed on our ward.
What problem does this paper attempt to address?